Selank (TP-7)

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from tuftsin, an endogenous immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg), with the addition of a Pro-Gly-Pro sequence that increases its stability and extends its duration of action. The peptide was developed as an anxiolytic and nootropic compound and has been approved as a prescription medication in Russia for anxiety and neurasthenia. Research has demonstrated effects on neurotransmitter systems, brain-derived neurotrophic factor (BDNF), and immune function.

Selank's mechanism involves multiple neurobiological systems: **GABAergic Modulation:** Selank influences GABA-A receptor expression and function, enhancing inhibitory neurotransmission. This contributes to its anxiolytic effects without the sedation associated with benzodiazepines. **Monoamine System Effects:** The peptide affects serotonin, dopamine, and norepinephrine metabolism, helping to stabilize mood and cognitive function. It appears to normalize neurotransmitter imbalances rather than causing direct stimulation or inhibition. **BDNF Enhancement:** Selank increases expression of brain-derived neurotrophic factor, a crucial protein for neuroplasticity, learning, and memory. This may underlie its nootropic properties. **Immune Modulation:** As a tuftsin derivative, Selank retains immunomodulatory properties, affecting cytokine production and immune cell function.